Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FFAR1 | O14842 | 2/20 | 0.47 |
| ▸ | MAPT | P10636 | 1/20 | 0.46 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.46 |
| ▸ | S1PR1 | P21453 | 7/20 | 0.44 |
| ▸ | S1PR3 | Q99500 | 3/20 | 0.44 |
| ▸ | S1PR2 | O95136 | 2/20 | 0.44 |
| ▸ | S1PR5 | Q9H228 | 3/20 | 0.44 |
| ▸ | S1PR4 | O95977 | 2/20 | 0.44 |
| ▸ | CYSLTR2 | Q9NS75 | 1/20 | 0.43 |
| ▸ | CYSLTR1 | Q9Y271 | 1/20 | 0.43 |
| ▸ | LTB4R | Q15722 | 1/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.43 |
| ▸ | NR1H4 | Q96RI1 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26206414 | 0.90 | LMNA (0.54) | FFAR1LMNAL3MBTL1 | |
| SCHEMBL22525650 | 0.87 | S1PR1 (0.44) | MAPTS1PR1S1PR3S1PR2S1PR5 | |
| SCHEMBL26206374 | 0.86 | PPARA (0.51) | FFAR1MAPTRXFP1CYSLTR2CYSLTR1 | |
| SCHEMBL26206480 | 0.85 | FFAR4 (0.39) | FFAR1MAPTRXFP1S1PR1S1PR3 | |
| SCHEMBL26206322 | 0.84 | MAPT (0.43) | MAPTRXFP1S1PR1S1PR3S1PR2 | |
| SCHEMBL26206388 | 0.83 | MAPT (0.50) | FFAR1MAPTRXFP1S1PR1S1PR3 | |
| SCHEMBL26206373 | 0.83 | TBXA2R (0.37) | MAPTRXFP1S1PR1LTB4R | |
| SCHEMBL26206478 | 0.83 | FOS (0.38) | LTB4R | |
| SCHEMBL26206484 | 0.83 | FFAR4 (0.37) | MAPTRXFP1S1PR1S1PR3S1PR2 | |
| SCHEMBL26206481 | 0.83 | TSHR (0.44) | FFAR1MAPTRXFP1S1PR1S1PR3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11746120-B2 | Stat degraders and uses thereof | KYMERA THERAPEUTICS, INC. (US) | 2023-09-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11746120-B2 | Stat degraders and uses thereof | STAT4, STAT1, STAT3 | FFAR1 4114/4885MAPT 3167/4885RXFP1 2746/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.